Earlier this week US hedge fund investor Kyle Bass got the wires buzzing when he reportedly outlined his plans to wage an inter partes review (IPR) war on big pharma at the USPTO’s Patent Trial and Appeal Board (PTAB). According to Bass, pharmaceutical companies are ripe for attack because of their predilection for regurgitating what he claims are essentially the same products under slightly tweaked patents to extend their IP protection.

Want to read more?

Register to access two of our subscriber-only articles per month

Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts

Already registered? Log in

What our customers are saying

Very impressed. Clear, usable insights into the business of IP, and particularly awareness of new strategic IP concepts and tools. I also find it effective for helping frame IP issues with clients and benchmarking to IAM best practice examples. Compares well with the LES journal, and both together cover a broad and thorough toolkit for any IP-centric businessperson.

David Todd
President/IP strategy consultant
Isentient Technologies Corp

Benefits

Subscribe to receive access to the full range of premium business intelligence, insights and analysis, as well as our IP directories, guides and daily news.

Why subscribe?